Targetcancer Foundation is ranked #3 of 6 medical research organizations in Cambridge, MA, with an America's Best Score of 72 out of 100, based on its 2025 Form 990.
Targetcancer Foundation is a 501(c)(3) organization, classified under Medical Research (NTEE H30). Contributions are tax-deductible.
955 Massachusetts Ave Ste 343, Cambridge, MA 02139-3233
Among the 8 scored medical research organizations in Cambridge, Targetcancer Foundation holds 14.5 months of operating reserves (peer median 24 months), runs a typical yearly surplus of 20.1% (peers: surplus of 18.9%), and has grown spending 9.1% a year (peers: grown spending 14.1% a year).
In fiscal year 2025 it reported $1,261,609 in revenue and $839,048 in expenses, with contributions making up 103.7% of revenue.
Target: Cancer Foundation promotes the development of lifesaving treatment protocols for rare cancers. Target: Cancer Foundation directly supports initiatives at the forefront of cancer treatment by funding innovative research, fostering collaborations, and raising awareness among scientists, clinicians, and patients.
Main program · fiscal year 2025
The specific purposes of the Organization are to raise awareness of and support for research into rare cancers, and to directly support patients and families facing rare cancers. This was accomplished in the fiscal year through the ongoing operation of a rare cancer precision medicine clinical trial, and through other programs. In 2020, Target: Cancer Foundation launched a rare cancer precision me… Read more
The specific purposes of the Organization are to raise awareness of and support for research into rare cancers, and to directly support patients and families facing rare cancers. This was accomplished in the fiscal year through the ongoing operation of a rare cancer precision medicine clinical trial, and through other programs. In 2020, Target: Cancer Foundation launched a rare cancer precision medicine clinical trial called TCF-001 TRACK (Target Rare Cancer Knowledge). TRACK is a 400-patient clinical trial studying genomics and precision medicine in rare cancers, providing patients with critical personalized genomic data about their cancer and treatment recommendations from a panel of field leaders, and also generating rare cancer research data. TRACK is developed, sponsored and managed by Target: Cancer Foundation, and is currently over halfway through its enrollment of patients with rare cancers and cancer of unknown primary.In 2024, Target: Cancer Foundation held a major scientific meeting- the Think Tank on Advancing Precision Medicine in Rare Cancers. This unique, innovative meeting unites key stakeholders including clinicians, researchers, government, industry, and patients and advocates. This meeting is specifically designed to promote collaboration, information-sharing and idea generation in an effort to define research priorities, foster new collaborative efforts across institutions, and ultimately propel the field forward.In 2024, Target: Cancer Foundation launched its Patient Outreach, Education and Support Program, which provides online and downloadable educational resources designed for patients navigating a rare cancer diagnosis. Theis includes resources such as What is a Rare Cancer, Initial Steps for Navigating a Rare Cancer Diagnosis, Clinical Trials, and Biomarker Testing. In addition, this program includes an educational webinar series intended for patients and caregivers.
$508,441 spent
Where each dollar went · fiscal year 2025
Of every dollar it spent, 61¢ went to programs, 26¢ to management and 13¢ to fundraising.
Programs $508,441
Management $222,602
Fundraising $108,005
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
61%
Below
Compared with Cambridge peers
Measure
This organization
Peer median
Operating reserves
14.5 mo
24.0 mo
Typical margin
+20.1%
+18.9%
Spending growth
+9.1% / yr
+14.1% / yr
Debt load
0.0%
1.6%
Peers: the 8 Cambridge medical research organizations with a score, ranked or below the bar.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$1,261,609Fiscal year 2025
Expenses$839,048Fiscal year 2025
Total assets$1,016,178Fiscal year 2025
Total liabilities$0Fiscal year 2025
Fiscal year ending January2025
Revenue$1,261,609
Expenses$839,048
Net income$422,561
Net assets$1,016,178
Notable sources of revenue
Percent of total revenue
Contributions
$1,308,131
103.7%
Program services
$0
0.0%
Investment income
$29,761
2.4%
Other (net)
−$76,283
−6.0%
Assets / debt
Total assets
$1,016,178
Total liabilities
$0
Net assets
$1,016,178
Compensation
Not in our extract for this year.
Fiscal year ending January2024
Revenue$676,451
Expenses$797,674
Net income−$121,223
Net assets$523,908
Notable sources of revenue
Percent of total revenue
Contributions
$674,113
99.7%
Program services
$0
0.0%
Investment income
$2,338
0.3%
Other (net)
$0
0.0%
Assets / debt
Total assets
$523,908
Total liabilities
$0
Net assets
$523,908
Compensation
Not in our extract for this year.
Fiscal year ending January2023
Revenue$846,106
Expenses$704,653
Net income$141,453
Net assets$645,131
Notable sources of revenue
Percent of total revenue
Contributions
$841,881
99.5%
Program services
$0
0.0%
Investment income
$1,819
0.2%
Other (net)
$2,406
0.3%
Assets / debt
Total assets
$645,131
Total liabilities
$0
Net assets
$645,131
Compensation
Officers and key employees
$173,092
Share of expenses
24.6%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?